Subcutaneous injection of IHP-102 prevents lung vaso-occlusion in sickle cell disease mice
Rikesh K. Dubey,
Ravi Vats,
Tomasz Brzoska,
Tomasz W. Kaminski,
Omika Katoch,
Jesus Tejero,
Gabriel Njikang,
John Paderi,
Prithu Sundd
Affiliations
Rikesh K. Dubey
Thrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA
Ravi Vats
Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA
Tomasz Brzoska
Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA
Tomasz W. Kaminski
Thrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA
Omika Katoch
Thrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA
Jesus Tejero
Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA; Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
Gabriel Njikang
IHP Therapeutics, San Carlos, CA
John Paderi
IHP Therapeutics, San Carlos, CA
Prithu Sundd
Thrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI, USA; Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA; Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Sickle Cell Center of Excellence, University of Pittsburgh, Pittsburgh, PA
